Trial Profile
Assessment of pleiotropic and proteinuria reducing effect of irbesartan and losartan in chronic kidney disease patients.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Mar 2020
Price :
$35
*
At a glance
- Drugs Irbesartan (Primary) ; Losartan (Primary)
- Indications Hypertension
- Focus Pharmacodynamics
- 16 Mar 2020 Status changed from recruiting to completed.
- 11 Sep 2009 New trial record